Corcept Therapeutics (NASDAQ: CORT) reported strong Q2 2026 results, with adjusted EPS of $0.22, beating estimates of $0.02, and revenue of $256.1 million, ahead of the $216.4 million consensus. Growth was driven by strong Korlym sales. The company also raised its full-year 2026 revenue guidance to $1.06–$1.09 billion, up from $975 million–$1.025 billion, and highlighted the recent FDA approval of relacorilant for platinum-resistant ovarian cancer. Sector: Biotechnology Key Highlights 💰 Q2 adjusted EPS: $0.22 vs. $0.02 estimate 📈 Revenue: $256.1 million vs. $216.4 million estimate 💊 Strong Korlym sales drove quarterly growth 📊 Raised 2026 revenue guidance to $1.06–$1.09 billion ✅ Recently received FDA approval for relacorilant in platinum-resistant ovarian cancer Why It Matters Corcept's earnings beat, higher revenue guidance, and recent FDA approval reinforce the company's strong commercial momentum and growth outlook, supporting investor confidence in its expanding oncology and endocrinology portfolio. https://www.thinksabio.com/reports/isr/CORT